昊帆生物
(301393)
| 流通市值：27.21亿 | | | 总市值：69.79亿 |
| 流通股本：4210.48万 | | | 总股本：1.08亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 171,932,875.31 | 602,261,319.28 | 434,698,213.66 | 270,298,471.51 |
| 营业收入 | 171,932,875.31 | 602,261,319.28 | 434,698,213.66 | 270,298,471.51 |
| 二、营业总成本 | 140,790,057 | 485,012,926.06 | 336,820,135.14 | 200,149,046.57 |
| 营业成本 | 110,891,430.64 | 392,510,570.71 | 266,268,640.36 | 161,306,618.37 |
| 税金及附加 | 1,647,328.41 | 6,604,271.85 | 4,667,491.6 | 2,656,055.4 |
| 销售费用 | 3,898,874.45 | 16,392,168.35 | 12,726,014.71 | 8,051,955.73 |
| 管理费用 | 12,469,471.41 | 36,854,852.51 | 30,740,506.56 | 14,923,747.55 |
| 研发费用 | 10,685,900.81 | 40,928,280.5 | 30,612,903.47 | 19,260,122.3 |
| 财务费用 | 1,197,051.28 | -8,277,217.86 | -8,195,421.56 | -6,049,452.78 |
| 其中:利息费用 | 152,492.53 | 698,037.91 | 504,290.66 | 49,404.41 |
| 其中:利息收入 | 2,295,656.68 | 16,468,599.34 | 12,832,185.57 | 7,544,180.7 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,532,114.61 | 7,240,295.4 | 7,813,884.37 | 5,444,086.14 |
| 加:投资收益 | 1,255,693.12 | 17,251,963.74 | 12,609,547.77 | 9,950,840.4 |
| 资产处置收益 | 58,841.59 | -907,512.14 | -93,989.15 | -93,989.15 |
| 资产减值损失(新) | -626,884.4 | -6,602,917.21 | -13,243,008.25 | -610,495.36 |
| 信用减值损失(新) | -1,087,472.05 | 2,357,860.4 | 3,740,734.34 | -387,503.22 |
| 其他收益 | 2,411,926.8 | 7,667,041.29 | 5,894,088.12 | 2,653,970.82 |
| 四、营业利润 | 37,687,037.98 | 144,255,124.7 | 114,599,335.72 | 87,106,334.57 |
| 加:营业外收入 | 18,436.71 | 172,233 | 116,822.93 | 44,752.12 |
| 减:营业外支出 | 75,730.21 | 15,157,159.4 | 889,406.87 | 31,795.45 |
| 五、利润总额 | 37,629,744.48 | 129,270,198.3 | 113,826,751.78 | 87,119,291.24 |
| 减:所得税费用 | 4,915,705.02 | 18,425,875.56 | 14,588,403.86 | 11,234,489.25 |
| 六、净利润 | 32,714,039.46 | 110,844,322.74 | 99,238,347.92 | 75,884,801.99 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 32,714,039.46 | 110,844,322.74 | 99,238,347.92 | 75,884,801.99 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 33,444,698.56 | 114,650,719.19 | 99,238,347.92 | 75,884,801.99 |
| 少数股东损益 | -730,659.1 | -3,806,396.45 | - | - |
| 扣除非经常损益后的净利润 | 27,792,400.54 | 104,433,657.15 | 81,271,955.04 | 62,000,384.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.31 | 1.07 | 0.93 | 0.71 |
| (二)稀释每股收益 | 0.31 | 1.07 | 0.92 | 0.7 |
| 八、其他综合收益 | 77,060.21 | 106,026.85 | 132,740.77 | 142,913.01 |
| 归属于母公司股东的其他综合收益 | 77,060.21 | 106,026.85 | 132,740.77 | 142,913.01 |
| 九、综合收益总额 | 32,791,099.67 | 110,950,349.59 | 99,371,088.69 | 76,027,715 |
| 归属于母公司股东的综合收益总额 | 33,521,758.77 | 114,756,746.04 | 99,371,088.69 | 76,027,715 |
| 归属于少数股东的综合收益总额 | -730,659.1 | -3,806,396.45 | - | - |
| 公告日期 | 2026-04-24 | 2026-04-17 | 2025-10-29 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |